Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Profit After Tax fell 11091.16% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$401.3 million, marking a year-over-year decrease of 15950.77%. This contributed to the annual value of $673.7 million for FY2024, which is 29135.13% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Profit After Tax stood at -$103.4 million, which was down 11091.16% from -$112.0 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Profit After Tax registered a high of $1.9 billion during Q1 2021, and its lowest value of -$112.0 million during Q2 2025.
  • For the 5-year period, Agios Pharmaceuticals' Profit After Tax averaged around $73.1 million, with its median value being -$89.3 million (2025).
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 475601.4% in 2021, then plummeted by 36266.22% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' Profit After Tax (Quarter) stood at -$94.6 million in 2021, then soared by 138.6% to $36.5 million in 2022, then crashed by 362.66% to -$95.9 million in 2023, then decreased by 0.61% to -$96.5 million in 2024, then decreased by 7.16% to -$103.4 million in 2025.
  • Its Profit After Tax was -$103.4 million in Q3 2025, compared to -$112.0 million in Q2 2025 and -$89.3 million in Q1 2025.